HOME>Investor Relations

Investor Relations

Share Price Information

IR Calendar

2019
October 30
Announcement of FY2019 2nd Quater Financial Results
July 29
Announcement of FY2019 1st Quater Financial Results
June 21
The 12th Ordinary General Meeting of Shareholders

What's New

  • RSS
  • About RSS

News Release List

2019
November 27 Release Launch of Alesion LX Ophthalmic Solution 0.1% in JapanPDF
November 25 Release Mitsubishi Tanabe Pharma Announces the Start of a Phase 3 Clinical Trial using Oral Suspension of Edaravone for ALSPDF
November 18 Release Announcement of Mitsubishi Tanabe Pharma Corporation’s Opinion RegardingTender Offer for Shares in Mitsubishi Tanabe Pharma Corporation by the Controlling Shareholder Mitsubishi Chemical Holdings Corporation, and Recommendation to Tender SharesPDF
November 18 Topics To Our Shareholders: Notice of Statement of Opinion Regarding Tender Offer for Mitsubishi Tanabe’s Shares by Mitsubishi Chemical Holdings Corporation, and Recommendation to Tender SharesPDF
November 11 Release Mitsubishi Tanabe Pharma Corporation Announces Results of the MT-7117 ENDEAVOR Study for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP)PDF
November 11 Release HIF-PH Inhibitor Vadadustat (MT-6548) Japan Phase 3 results for the treatment of renal anemia at American Society of Nephrology, Kidney Week 2019PDF
November 11 Topics Mitsubishi Tanabe Pharma Corporate Report 2019
November 1 Topics IR Meeting for FY2019 2nd Quarter Business Results[Transcript]
October 31 Topics IR Meeting for FY2019 2nd Quarter Business Results[Audio]
October 30 Release Announcement of FY2019 2nd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
October 30 Topics IR Meeting for FY2019 2nd Quarter Business Results[Material]
October 25 Release Revision to the First Half Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2020PDF
October 25 Release Vadadustat (MT-6548) Japan Phase 3 results for treatment of renal anemia to be presented at ASN Kidney Week 2019PDF
October 11 Topics Corporate Governance
Corporate Governance Report
October 9 Release Mitsubishi Tanabe Pharma enters into a licensing agreement with Viela Bio for inebilizumab, a treatment agent for neuromyelitis optica spectrum disorder, in Japan and other Asian regionsPDF
October 2 Topics Opinion Sharing Meeting on ESG [Transcript]
October 2 Release Notification of acceptance of the New Drug Submission for Scientific Review of VLP Seasonal Influenza Vaccines(MT-2271)by Health CanadaPDF
October 1 Topics CSR Information updated
September 30 Topics Opinion Sharing Meeting on ESG [Video]
September 30 Release Mitsubishi Tanabe Pharma to participate in new screening program through the Global Health Innovative Technology Fund ~Targeting treatments for infectious diseases that burden the developing countries~PDF
September 27 Topics Opinion Sharing Meeting on ESG [Material]
September 24 Release NMPA accepts our filing for TENELIA, a treatment agent for type 2 diabetes mellitus in ChinaPDF
September 20 Release Notice Regarding the Conclusion of Joint Sales Promotion Contract Concerning Alesion Ophthalmic Solution 0.05% and Alesion LX Ophthalmic Solution 0.1% between Mitsubishi Tanabe Pharma and Santen Pharmaceutical Co., Ltd.PDF
September 18 Topics Mitsubishi Tanabe Pharma Included in the Dow Jones Sustainability Asia Pacific Index
September 17 Release Mitsubishi Tanabe Pharma and Daiichi Sankyo announce alliance for ALS treatment agent edaravone in BrazilPDF
September 4 Release Notice regarding the launch of Collategene intramuscular injection 4 mg, an HGF gene therapy productPDF
August 30 Topics Monitoring indicators on “Materiality”
August 28 Release The Start of a Phase 3 Clinical Trial of Continuous Subcutaneous Liquid levodopa/carbidopa Administration (ND0612) for patients with fluctuating Parkinson’s diseasePDF
August 8 Release PhaseⅠClinical Trial study protocol for MT-3921 in Patients with Spinal Cord Injury submitted to the US INDPDF
August 8 Release Regulatory Approval for Marketing Cariprazine (MP-214) for the Treatment of Schizophrenia in Part of the ASEAN (Singapore and Thailand)PDF
August 7 Release NMPA approved Japan-originated ALS treatment Edaravone in ChinaPDF
August 6 Release Commencement of R&D of Gene Therapy Product for Hemophilia BPDF
July 31 Topics IR Meeting for FY2019 1st Quarter Business Results[Transcript]
July 29 Topics IR Meeting for FY2019 1st Quarter Business Results[Material][Audio]
July 29 Release Announcement of FY2019 1st Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
July 23 Release Submission of Vadadustat (MT-6548) New Drug Application in Japan for renal anemiaPDF
June 24 Topics Corporate Governance Report
June 21 Topics Notice of Resolution of the 12th Ordinary General Meeting of Shareholders
⇒Results of the Exercise of Voting Rights(June 24, 2019)
May 30 Release Withdrawal of Marketing Authorization Application of edaravone for ALS in the European UnionPDF
May 29 Release Launch of SIMPONI Subcutaneous Injection 50mg AutoinjectorPDF
May 24 Topics Notice of Convocation of the 12th Ordinary General Meeting of Shareholders
May 16 Topics IR Meeting for FY2018 Business Results[Transcript]
May 13 Topics IR Meeting for FY2018 Business Results[Material][Video]
May 10 Release Announcement of Financial Results for FY2018
⇒R&D Pipeline "State of New Product Development"
May 7 Topics Analysts meeting on Revision to Consolidated Financial Forecasts for FY2018[Transcript]
April 26 Release Mitsubishi Tanabe Pharma and Salix enter into a licensing agreement for MT-1303, a therapeutic agent for autoimmune diseasesPDF
April 26 Topics Medicago announced that its proprietary plant-based production platform, Proficia was awarded "Best New Vaccine Technology/Platform" at the World Vaccine Congress in Washington, D.C.
April 24 Topics Analysts meeting on Revision to Consolidated Financial Forecasts for FY2018 [Material][Audio]
April 24 Release Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019PDF
April 15 Release For the ALS patients in the world, we hope to deliver Japan-originated ALS treatment―NMPA accepts our filing for Radicut to treat ALS in ChinaPDF
April 11 Release Notice Regarding Reorganization of Research, Production, and Technology BasesPDF
March 28 Release The Global Health Innovative Technology Fund provides grant for joint research into anti-malarial drugs conducted by Mitsubishi Tanabe Pharma and a malaria research institutionPDF
March 20 Release Aiming to expand our sales and to strengthen our business foundations in the growing ASEAN market Establishment of sales subsidiary in Malaysia and Vietnam Representative OfficePDF
March 12 Release Topline Results of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Anemia due to CKDPDF
February 28 Release Tianjin Tanabe and Servier Tianjin join hands to promote TENELIA in ChinaPDF
February 20 Release Mitsubishi Tanabe Pharma Received Notice of Request for ArbitrationPDF
February 14 Release FDA accepted an Investigational New Drug Application for MT-8633, an ADC Targeting cMet Positive Solid TumorsPDF
February 12 Release First Initiative in Digital Medicine Notice Regarding the Start of a Demonstration Project for TOMOCO, a Diabetes Care AppPDF
February 7 Topics IR Meeting for FY2018 3rd Quarter Business Results[Transcript]
February 6 Release Swissmedic approves RADICAVA, Japan-originated ALS treatmentPDF
February 4 Topics IR Meeting for FY2018 3rd Quarter Business Results[Material][Audio]
February 4 Release Announcement of FY2018 3rd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
February 4 Release Notice Regarding Conclusion of Stock Transfer Agreement for Tanabe Seiyaku Yoshiki Factory Co., Ltd.PDF
  • Dow Jones Sustainability Indices
  • FTSE4Good
  • FTSE Blossom Japan
  • MSCI Japan Empowering Women Index(WIN)
  • JPX-NIKKEI 400

※ THE INCLUSION OF Mitsubishi Tanabe Pharma Corporation IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF Mitsubishi Tanabe Pharma Corporation BY MSCI OR ANY OF ITS AFFILIATES.
THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES.

Investor Relations

Share Price Information

ReadSpeaker docReader makes documents accessible to all users including users with vision problems letting users view and listen to texts.
User guide